Taiwanese vaccine maker Adimmune Corp (國光生技) yesterday said it has received approval from the Chinese government for it to start phase three clinical trials of its flu vaccine in China, enabling it to enter the market next year.
The company plans to launch the vaccine immediately after receiving Chinese approval in the first half of next year, company vice president Simon Kao (高聖凱) said.
The company expects to sell less than 1 million vials of vaccine in China next year, but the volume should increase to between 3 million and 5 million vials in 2016, accounting for 10 percent of the market, Kao said.
There are currently 10 companies making flu vaccines in 0.5cc vials, and nine making 0.25cc vials. Adimmune is capable of making vaccines in both sizes, Kao said.
Flu vaccine in China is priced between 10 yuan and 60 yuan (US$1.65 and US$9.85) per vial, while the average price of Adimmune’s will be between 50 yuan and 60 yuan, Kao said.
The company sells 1.5 million vials of flu vaccine in Taiwan at between NT$100 to NT$150 each, it said, adding that domestic sales of the vaccine would account for 40 percent of its revenue this year.
Thanks to the Cross-strait Cooperation Agreement on Medicine and Public Health Affairs (兩岸醫藥衛生合作協議), the company spent only three years to get the green light to start the phase three trials, shorter than five to six years for other companies, Kao said.
“We will be the first company to launch a medical product in China without building a plant there,” chairman Steve Chan (詹啟賢) said.
Meanwhile, Chan said Adimmune’s vaccine for H7N9 avian influenza will complete phase one clinical trails by January and phase two clinical trials by June.
From January through last month, the company posted revenue of NT$273.8 million (US$9.32 million), up 18.23 percent from NT$231.57 million a year ago, as sales to its partner, Dutch-based Crucell, rose to 370g from 200g last year, chief financial officer Vic Chang (張哲瑋) said.
Sales to Crucell, which account for 60 percent of the company’s revenue this year, are expected to increase next year as the company started to provide about 75g to 100g adjuvants for curing hepatitis A, which are twice as expensive as its flu vaccine, Chang said.
Adimmune is likely to remain in the red this year, he said.
The company reported losses of NT$309.25 million in the first half of the year, compared with losses of NT$284.74 million a year ago.
Adimmune‘s shares rose 6.07 percent to NT$47.15 yesterday.
ASE Technology Holding Co (ASE, 日月光投控) yesterday launched its second testing facility in San Jose, California, to expand advanced chip testing capacity such as burn-in testing to satisfy customers’ rising engineering needs for emerging semiconductor applications, such as artificial intelligence (AI) and high-performance computing (HPC). ISE Labs Inc, a fully owned subsidiary of ASE, would operate the advanced testing facility. When added to its first facility in nearby Fremont, ISE would double its available research-and-development lab and business space to 150,000m2 in hopes of boosting the US semiconductor supply chain, the company said in a statement. “As the semiconductor manufacturing supply chain reshoring
VALUE: TSMC’s market capitalization far exceeds the combined size of all the Latin American companies on MSCI Inc’s benchmark for emerging markets Taiwan Semiconductor Manufacturing Co’s (TSMC, 台積電) US$420 billion equity rally this year would get a valuation test this week when it reports earnings, with analysts expecting the chipmaker to raise full-year sales forecasts. The world’s biggest contract chipmaker would probably report a 29 percent increase in second-quarter net income on Thursday, according to the median estimate of analysts surveyed by Bloomberg. More importantly, analysts from JPMorgan Chase & Co to Morgan Stanley expect it to also raise its full-year sales guidance, justifying another round of valuation expansion. Just like Nvidia Corp, TSMC has become a favorite artificial intelligence (AI)-bet for investors with
ASSASSINATION ATTEMPT: The previous shooting targeting a US president or major party candidate was the 1981 incident targeting then-US president Ronald Reagan Saturday’s shooting at former US president Donald Trump’s election rally raises his odds of winning back the White House, and trades betting on his victory would increase this coming week, investors said yesterday. Trump was shot in the ear during the rally in Pennsylvania on Saturday in what the authorities were treating as an assassination attempt. Trump, his face spattered with blood, pumped his fist moments after the attack, and his campaign said he was fine after the incident. Before the shooting, markets had reacted to the prospect of a Trump presidency by pushing the US dollar higher and positioning for a
President William Lai (賴清德) yesterday thanked memory chipmaker Micron Technology CEO Sanjay Mehrotra for his trust and continued investment in Taiwan, in a rare public meeting with a senior foreign tech executive. It is very unusual for Taiwan’s president to have publicized meetings with senior foreign tech executives, despite the nation being home to the world’s largest contract chipmaker, Taiwan Semiconductor Manufacturing Co (TSMC, 台積電), whose chips help to power the surge in artificial intelligence (AI) applications. Lai thanked Mehrotra for “showing trust and support for Taiwan” in a video released by the Presidential Office. “I want to thank Micron for its long-term